anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The early detection and accurate diagnosis of liver fibrosis, a progressive and potentially serious liver condition, are crucial for effective medical intervention. Invasive methods like biopsies for diagnosis can be risky and expensive. This research presents a novel computer-aided diagnosis model for liver fibrosis using a hybrid approach of minimum redundancy maximum relevance (MRMR) feature selection, bidirectional long short-term memory (BiLSTM), and convolutional neural networks (CNN). The proposed model involves multiple stages, including image acquisition, preprocessing, feature representation, fibrous tissue identification, and classification. Notably, histogram equalization is employed to enhance image quality by addressing variations in brightness levels. Performance evaluation encompasses a range of metrics such as accuracy, precision, sensitivity, specificity, F1 score, and error rate. Comparative analyses with established methods like DCNN, ANN-FLI, LungNet22, and SDAE-GAN underscore the efficacy of the proposed model. The innovative integration of hybrid MRMR-BiLSTM-CNN architecture and the horse herd optimization algorithm significantly enhances accuracy and F1 score, even with small datasets. The model tackles the complexities of hyperparameter optimization through the IHO algorithm and reduces training time by leveraging MRMR feature selection. In practical application, the proposed hybrid MRMR-BiLSTM-CNN method demonstrates remarkable performance with a 97.8% accuracy rate in identifying liver fibrosis images. It exhibits high precision, sensitivity, specificity, and minimal error rate, showcasing its potential for accurate and non-invasive diagnosis.
INTRODUCTION: Patients with end-stage heart failure have limited options for medical treatment, and this ultimately necessitates heart transplantation. Patients undergoing heart transplant surgery are burdened with substantial costs related to finances, procedural risks, and postoperative quality of life. This report presents a case of heart failure in a patient whose limbs and heart were preserved through a collaboration between modern and traditional Chinese medicine (TCM).
PATIENT PRESENTATION: A 47-year-old man was admitted to the emergency department with out-of-hospital cardiac arrest (OHCA) and was diagnosed with 3-vessel disease and acute decompensated heart failure on October 27, 2020. After extracorporeal membrane oxygenation (ECMO), the patient presented with cyanosis and gangrene in all four limbs. Cardiologists and plastic surgeons recommended heart transplantation and amputation. The patient wanted to keep his limbs and heart intact and requested to receive TCM. A TCM physician was consulted by visiting staff to provide combined care. After TCM intervention, both the ejection fraction (EF) and gangrene improved. Until now, the patient continues to receive TCM treatment, lives with preserved limbs and heart, and went through SARS-CoV2 infection smoothly in 2023.
CONCLUSION: TCM met the expectations of the patient and reduced the high medical expenses. This approach may improve the outlook and be a more economical option for patients with end-stage heart failure.
BACKGROUND: Lactobacillus acidophilus is a commensal urinary bacterium found more abundantly in healthy individuals than in stone patients. Hence, it has been proposed to play an inhibitory role in kidney stone disease (KSD) but with unclear mechanisms. We therefore investigated the direct effects of L. acidophilus on calcium oxalate (CaOx) stone development compared with Escherichia coli, which is known to promote CaOx stone formation.
RESULTS: L. acidophilus at 1 × 103 CFU/ml  significantly reduced the abundance of newly formed crystals, enlargement and aggregation of seeded crystals, and crystal adhesion on renal cell membranes. By contrast, E. coli at 1 × 103 CFU/ml significantly enhanced crystal growth and aggregation but did not affect crystallization and crystal-cell adhesion. Oxalate consumption assay showed that neither L. acidophilus nor E. coli significantly reduced the remaining oxalate level after 1 - 3 h incubation. However, both of them adhered to CaOx crystals. Surface component detection revealed that only L. acidophilus expressed S-layer protein, whereas only E. coli exhibited flagella on their surfaces. Removal of L. acidophilus S-layer protein and E. coli flagella completely abolished the inhibitory and promoting effects of L. acidophilus and E. coli, respectively.
CONCLUSIONS: L. acidophilus inhibits CaOx stone development by hampering crystallization, growth, aggregation and cell-adhesive ability of CaOx. By contrast, E. coli enhances CaOx stone development by promoting CaOx growth and aggregation. Their contradictory effects are most likely from differential surface components (i.e., S-layer protein on L. acidophilus and flagella on E. coli) not from oxalate-degrading ability. Video Abstract.
Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human mammal transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at a desired target, e.g., a tissue, or organ in need of cell replacement therapy. For providing cells and tissues for transplant to a non-human mammal, the cells and tissues can be isolated from a gastrulating embryo produced by same-species nuclear transfer. Histocompatible cells and tissues for transplant to a human can be isolated from a gastrulating embryo that (i) is genetically modified to be in capable of developing beyond and early stage, or (ii) is produced by cross-species nuclear transfer between a human nuclear donor cell and an enucleated recipient cell, e.g., an oocyte, of a non-human mammal, or (iii) is produced by androgenesis or gynogenesis, or from pluripotent stem cells generated from such an embryo. Methods for producing histocompatible cells and tissues for transplant to a human can also be used to produce such cells or tissues for transplant to non-human mammals. The present invention also provides model embryonic systems having defined genetic makeup that are useful for developing and testing methods for cell and tissue therapy, and for studying genetic imprinting, reprogramming, rejuvenation, and other biochemical, metabolic, and physiological phenomena associated with embryogenesis.
BACKGROUND: Bipolar disorder (BD) is a severe mental disorder with heavy disease burden. Females with BD are special populations who suffer a lot from childhood trauma, social support, cognitive deficits, and suicidality. In this study, the relationship among childhood trauma, social support, and clinical symptoms of BD was investigated and the risk factors for suicidality were explored in female patients with BD.
METHODS: This study included 57 drug-naive female BD patients, 64 female BD patients with long-term medication, and 50 age-matched female healthy controls. Childhood trauma, social support, clinical symptoms, cognition, and suicidality (suicide ideation, suicide plan, suicide attempt, suicide frequency) were measured with scales.
RESULTS: Compared with healthy controls, females with BD showed higher levels of childhood trauma and suicidality, and lower levels of social support and cognitive deficits. In the drug-naïve BD group, social support mediated the relationship between childhood trauma and insomnia symptoms (indirect effect: ab = 0.025). In the BD with long-term medication group, mania symptom was associated with suicide plan (OR = 1.127, p = 0.030), childhood trauma was associated with suicide attempt (OR = 1.088, p = 0.018), and years of education (OR = 0.773, p = 0.028), childhood trauma (OR = 1.059, p = 0.009), and delayed memory (OR= 1.091, p= 0.016) was associated with suicide frequency (OR = 1.091, p = 0.016).
CONCLUSIONS: This study provides initial evidence that social support partially explains the relationship between childhood trauma and clinical symptoms in females with BD. Additionally, mania symptoms, childhood trauma, and delayed memory were risk factors for suicidality. Interventions providing social support and improving cognitive function may be beneficial for females with BD who are exposed to childhood trauma and with high suicide risk.
The purpose of this study is to learn how medications participant will receive in the course of their delivery are metabolized (broken down by the body). The investigators hope to learn more about the way drugs are metabolized by pregnant women, and how those drugs are distributed in the blood and body compartments and cleared in the urine, and how maternal body weight affects the metabolism. With this information the investigators will be able to develop a treatment regimen considering factors in the body that affect magnesium levels so that the investigators can improve treatment of pregnant women. The goal of the study is to understand how different dosing of magnesium sulfate affects blood levels of the magnesium in larger women.

Magnesium sulfate is generally given to patients to protect the mother against seizures in the case of preeclampsia. Different hospitals in the United States use different doses of magnesium sulfate. Participants will receive one of two accepted doses of magnesium sulfate for preeclampsia. The dose is usually 4g - 6g at the start, with another dose of 2-3 g every hour until 24 hours after delivery. Participants will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete. Participants will receive magnesium sulfate in the course of their normal clinical care whether or not they participate in this study.
The present invention relates to a sugar reducing yoghurt, which belongs to the technical field of processing medical foods. The sugar reducing yoghurt is characterized in that the yoghurt contains the ingredient of broom cypresses which are sugar reducing medicinal plants; broom cypresses in the yoghurt are extraction juices of leaves and stalks of broom cypresses, broom cypress leaves or broom cypress stalks. Through the technical scheme of the present invention, the original mouth feel and the original flavor of yoghurt is maintained in yoghurt products, and the nutritive value of the yoghurt of the present invention is enhanced; meanwhile, the yoghurt has a fresh color. Broom cypresses as an ingredient are added to the present invention, the defects of the shortage of the content of vitamins and inorganic salt existing in milk are overcome, and the present invention is particularly suitable for infants who have only few vegetables and fruits. The product of the present invention has the advantages of simple preparing method, locally obtained broom cypress and whole plant, easily acquired medicinal material with low price, low manufacturing cost, obvious effect on the treatment of diabetes through reducing blood sugar, and no toxic and side effect. The present invention is suitable for most people's eating habits, has universal application for a long term and also has the function of health care; consequently, the sugar reducing yoghurt has a broad market prospect.
Study Overview. The overarching aim of this proposal is to test the efficacy of structured financial incentives intervention (FINANCE-DM) comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives; compared to an active control group (nurse education and home telemonitoring alone) on glycemic control. The study also will evaluate whether intervention effects are sustained 6 months after the financial incentives are withdrawn (i.e. 18 months post randomization); and whether the intervention is differentially efficacious across racial/ethnic groups. Equal number of patients from three racial/ethnic groups (150 Whites, 150 AAs and 150 HAs, total sample of 450) will be randomized to FINANCE-DM intervention (n=225) or an active comparator group (n=225), so that within each racial/ethnic group, half (75 patients) will be randomized to the FINANCE-DM intervention group and the other half (75 patients) will be randomized to the active comparator group. Primary aims are to test overall efficacy across combined racial/ethnic groups; efficacy within racial/ethnic groups and cost effectiveness for the primary endpoint (glycemic control). Secondary aim is to test efficacy on secondary endpoints including BP, LDL, QOL and self-care behaviors. Each patient will be followed for 12 months (long-term effect) and 18 months (sustainability effect), with study visits at baseline, 3, 6, 9, 12 and 18 months. The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. The active comparator group will receive the same nurse education and home telemonitoring intervention as the FINANCE-DM group, on the same schedule, and for the same duration . The only difference is that participants will not receive structured financial incentives.
KENGREAL is intended for IV administration, after reconstitution and dilution.

Preparation

Reconstitute the vial prior to dilution in a bag. For each 50 mg/vial, reconstitute by adding 5 mL of Sterile Water for Injection. Swirl gently until all material is dissolved. Avoid vigorous mixing. Allow any foam to settle. Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colorless to pale yellow solution. Parenteral drug products should be inspected visually for particulate matter after reconstitution.

Before administration, each reconstituted vial must be diluted further with Normal Saline (Sodium Chloride Injection 0.9% USP) or 5% Dextrose Injection USP.

Withdraw the contents from one reconstituted vial and add to one 250 mL saline bag. Mix the bag thoroughly. This dilution will result in a concentration of 200 mcg/mL and should be sufficient for at least 2 hours of dosing. Patients 100 kg and over will require a minimum of 2 bags.

Reconstituted KENGREAL should be diluted immediately. Diluted KENGREAL is stable for up to 12 hours in 5% Dextrose Injection and 24 hours in Normal Saline at Room Temperature. Discard any unused portion of reconstituted solution remaining in the vial.

Administration

Administer KENGREAL via a dedicated IV line.

Administer the bolus volume rapidly (<1 minute), from the diluted bag via manual IV push or pump. Ensure the bolus is completely administered before the start of PCI. Start the infusion immediately after administration of the bolus [see Dosage and Administration (2.1)].
Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
Plantar fasciitis is one of the most common causes of heel pain; the pain is more intense in the morning, tends to decrease during the day with movement, to flare up after sitting for a long time. It presents itself as inflammation and contextual degeneration of the insertion of the fascia that covers the muscles present at the level of the sole of the foot, with progressive evolution and possible calcification of the insertion. The incidence is between 9 and 20% of the population, with a higher incidence in middle-aged obese women and in young male runners. The diagnosis makes use of radiography, to verify any local deformities or the presence of the subcalcaneal spur, and ultrasound, to investigate the integrity of the fascia and its thickening. MRI images are useful for better studying the heel bone and plantar fascia, especially for discerning other various causes of heel pain, including stress fractures, tarsal tunnel syndrome, and Achilles tendinopathy. Signal changes with bone edema are sometimes found in association with plantar fasciitis and may be indicative of or represent the result of avulsive trauma, stress, intraspongious fractures or a combination of these situations. These MRI images are similar to those described in the elbow in some patients with epicondylitis, where overuse can cause increased bone edema on T2-weights. Previous studies have shown the presence of bone edema at the level of the heel on MRI in 35% of patients with plantar fasciitis. Plantar fascia evaluation with a dedicated magnetic resonance scanner in weight-bearing position: our experience in patients with plantar fasciitis and in healthy volunteers. Maier et al demonstrated that the presence of calcaneal bone edema is a highly predictive factor for improved response to shock wave treatment. Often the finding of a thickening of the fascia and the signal changes of the soft tissues do not correlate with the clinical response, while the presence of bone edema is highly predictive (positive predictive value 0.94, sensitivity 0.89, specificity 0.8).
1,247,804. Antiseptic detergent composition. ETABS. CLIN-BYLA. 13 June, 1969 [28 June, 1968; 5 July, 1968], No. 30181/69. Headings A5B and A5E. [Also in Division C5] An antiseptic detergent composition comprises a stock solution of 3, 4, 4'-trichlorocarbanilide which contains dodecylbetaine or oxy-ethylenated castor oil, as solubilising agent for the 3, 4, 4'-trichlorocarbanilide, the solution remaining clear on subsequent aqueous dilution. The stock solution should preferably contain substantially 5% by weight, more preferably 0.5-5% by weight, 3, 4, 4'-trichlorocarbanilide and may be prepared by adding to an aqueous solution of dodecylbetaine or oxy-ethylenated castor oil, sufficient 3, 4, 4'-trichlorocarbanilide to saturate the aqueous solution and thereafter boiling the solution under reflux for more than 1 hour. These compositions are advantageously used as liquid soaps for disinfection and cleansing which may be diluted with water and further contain essential oils and anionic, cationic and non-ionic detergents. In addition the stock solution may be associated with various ingredients to constitute cosmetological and hygienic products. Examples based on a stock solution containing dodecylbetains describe deodorizing soap cakes which contain as the basic surface active ingredients soap, protein soap or sodium laurylsulphate and in addition polyethyleneglycol, perfume, stearic acid and starch; an after-shave lotion containing menthol, glycerine, perfume and ethyl alcohol; a massage lotion containing glycerine or sorbitol, perfume and ethyl alcohol; a liquid deodorizing and antiseptic soap containing aqueous dodecylbetaine, protein soap and perfume; an antiseptic cream shampoo containing aqueous dodecylbetaine, sodium laurylsulphate, protein soap, lauric acid diethanolamide, carboxymethylcellulose and perfume; a liquid antiseptic shampoo containing E.D.T.A. (sodium salt), aqueous dodecylbetaine and perfume; an antiseptic talc containing titanium dioxide and talc; an antiseptic and deodorizing gel containing ethylhydroxyethyl cellulose and perfume; an antiseptic and deodorizing alcohol bomb containing castor oil, perfume, ethyl alcohol and propellent gas; and an antiseptic and deodorizing cream containing perfume and polyethylene glycol ointment. Similar formulations may be obtained from stock solutions based on oxy-ethylenated castor oil and additionally containing E.D.T.A. (sodium salt), a triethanolamine salt of a condensation product of a fatty coconut acid with a polypeptide and amino acid complex and either lauric acid diethanolamide or sodium laurylsulphate.
The effectiveness of paroxetine in the treatment of panic disorder was demonstrated in three 10- to 12-week multicenter, placebo-controlled studies of adult outpatients (Studies 1 to 3). Patients in all studies had panic disorder (DSM-IIIR), with or without agoraphobia. In these studies, paroxetine was shown to be significantly more effective than placebo in treating panic disorder by at least 2 out of 3 measures of panic attack frequency and on the Clinical Global Impression Severity of Illness score.

Study 1 was a 10-week dose-range finding study; patients were treated with fixed paroxetine doses of 10, 20, or 40 mg/day or placebo. A significant difference from placebo was observed only for the 40 mg/day group. At endpoint, 76% of patients receiving paroxetine 40 mg/day were free of panic attacks, compared to 44% of placebo-treated patients.

Study 2 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) and placebo. At endpoint, 51% of paroxetine patients were free of panic attacks compared to 32% of placebo-treated patients.

Study 3 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) to placebo in patients concurrently receiving standardized cognitive behavioral therapy. At endpoint, 33% of the paroxetine-treated patients showed a reduction to 0 or 1 panic attacks compared to 14% of placebo patients.

In both Studies 2 and 3, the mean paroxetine dose for completers at endpoint was approximately 40 mg/day of paroxetine.

Long-term maintenance effects of paroxetine in panic disorder were demonstrated in an extension to Study 1. Patients who were responders during the 10-week double-blind phase and during a 3-month double-blind extension phase were randomized to either paroxetine (10, 20, or 40 mg/day) or placebo in a 3-month double-blind relapse prevention phase. Patients randomized to paroxetine were significantly less likely to relapse than comparably treated patients who were randomized to placebo.

Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
NEW MATERIAL:An allantoin derivative shown by the formula I (R is lower alkyl, cycloalkyl, or aryl; this lower alkyl group may be replaced with hydroxyl group or alkoxycarbonyl group). EXAMPLE:8-(1'Hydroxymethylpropyl)allantoin. USE:Showing antipeptic ulcer action, suppressing action on gastriointestinal disorder, protecting action on the skin, remedying action on skin disease or trauma, useful as an antipeptic ulcer, remedy for wound, etc. Also useful as an intermediate for synthesizing drugs. Being administered orally and parenterally. PREPARATION:A compound shown by the formula II is condensed with an amine shown by the formula R-NH2, to give a compound shown by the formula I . The condensation is preferably carried out by using a condensation agent such as N,N'-dicyclohexylcarbodiimide or its derivative, or N-ethoxycarbonyl-2- ethoxy-1,2-dihydroquinoline, etc.